The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ARDS in the setting of FOLFOX/cetuximab based chemoradiotherapy for locally advanced esophageal adenocarcinoma (E2205).
 
Ramla NAMISANGO Kasozi
No Relationships to Disclose
 
Anita Choudhary
No Relationships to Disclose
 
Michael K. Gibson
No Relationships to Disclose
 
Paul J. Catalano
Research Funding - Lilly/ImClone
 
Lawrence Kleinberg
No Relationships to Disclose
 
Charles A. Staley
No Relationships to Disclose
 
Lori J. Sokoll
No Relationships to Disclose
 
Wei Song
Leadership - JBS Science
Stock and Other Ownership Interests - JBS Science
 
Mary Frances Mulcahy
No Relationships to Disclose
 
Lawrence P. Leichman
No Relationships to Disclose
 
Al Bowen Benson
Consulting or Advisory Role - Alchemia; Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech/Roche; Genomic Health; Infinity Pharmaceuticals; IntegraGen; Lilly/ImClone; Merck Serono; Merck/Schering Plough; National Cancer Institute; Pharmacyclics; Precision Therapeutics; Sanofi; Spectrum Pharmaceuticals; Taiho Pharmaceutical; Vicus Therapeutics
Research Funding - advanced accelerator applications; Alchemia; Amgen; Astellas Pharma; AVEO; Bayer/Onyx; EMD Serono (Inst); Genentech (I); Gilead Sciences; Infinity Pharmaceuticals; Merck Serono (Inst); Novartis
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Bayer; Boehringer Ingelheim; Dava Oncology; Genentech/Roche; Gilead Sciences; Lilly/ImClone; Sanofi; Spectrum Pharmaceuticals; TRM Oncology